News Search Results
Jul 24, 2025, 09:00 ET Congruence Awarded Grant from The Michael J. Fox Foundation for Parkinson's Research (MJFF) to Advance Novel GCase Activators and Correctors for Parkinson's Disease with GBA1 Mutations
MONTREAL, July 24, 2025 /PRNewswire/ -- Congruence, a computationally-driven biotechnology company building a unique pipeline of correctors for diseases of protein misfolding, including MC4R-deficient genetic obesity, GBA-driven Parkinson's
More news about: Congruence Therapeutics
Jul 24, 2025, 09:00 ET Angel Yeast Showcases Innovative Yeast Protein at 2025 IFT FIRST in Chicago
solution, the non-alcoholic beer yeast NAO5. "Angel Yeast is always committed to the mission of 'Developing yeast biotechnology, innovate for a healthy life'," said Hang Tao. "We would also like to invite food manufacturers, industry partners
More news about: Angel Yeast
Jul 24, 2025, 09:00 ET Angel Yeast Showcases Innovative Yeast Protein at 2025 IFT FIRST in Chicago
solution, the non-alcoholic beer yeast NAO5. "Angel Yeast is always committed to the mission of 'Developing yeast biotechnology, innovate for a healthy life'," said Hang Tao. "We would also like to invite food manufacturers, industry partners
More news about: Angel Yeast
Jul 24, 2025, 09:00 ET Roche Diagnostics showcases science-driven leadership and innovation at ADLM 2025
Basel, Switzerland, as one of the first industrial manufacturers of branded medicines, Roche has grown into the world's largest biotechnology company and the global leader in in-vitro diagnostics. The company pursues scientific excellence to discover and develop medicines and diagnostics
More news about: Roche Diagnostics
Jul 24, 2025, 08:00 ET Anixa Biosciences Awarded New U.S. Patent Extending Breast Cancer Vaccine IP Protection into 2040s
Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced that the United States Patent and Trademark Office (USPTO) will issue
More news about: Anixa Biosciences, Inc.
Jul 24, 2025, 08:00 ET Lilly and Verve announce expiration of Verve tender offer
life-changing discoveries for nearly 150 years, and today our medicines help tens of millions of people across the globe. Harnessing the power of biotechnology, chemistry and genetic medicine, our scientists are urgently advancing new discoveries to solve some of the world's most significant health challenges:
More news about: Eli Lilly and Company
Jul 23, 2025, 16:51 ET ESSA Pharma Inc. Provides Update on its Application to the Supreme Court of British Columbia for Approval of an Interim Order and Cash Distribution to Shareholders
announced that, in connection with its previously announced business combination agreement with XenoTherapeutics, Inc. ("Xeno"), a non-profit biotechnology company, under which Xeno will acquire (the "Transaction") all of the issued and outstanding common shares of ESSA (the "Common Shares"),
More news about: ESSA Pharma Inc.
Jul 23, 2025, 16:06 ET RCKT Class Action Reminder: Robbins LLP Reminds Rocket Pharmaceuticals, Inc. Investors of the Class Action Lawsuit - Contact us for more information
between February 7, 2025 and May 26, 2025. Rocket is a fully integrated, late-stage biotechnology company focused on the development of gene therapies, with direct on-target mechanism of action and clear clinical endpoints, for rare and devastating
More news about: Robbins LLP
Jul 23, 2025, 16:05 ET Viking Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update
2025.Upcoming Investor Events. Viking management will participate in the following upcoming investor events:BTIG Virtual Biotechnology Conference 2025 VirtualJuly 29 – 30, 2025Cantor Global Healthcare
More news about: Viking Therapeutics, Inc.
Jul 23, 2025, 13:15 ET RCKT INVESTOR ALERT: Rocket Pharmaceuticals, Inc. Investors with Substantial Losses Have Opportunity to Lead Securities Class Action Lawsuit
Monday, August 11, 2025. CASE ALLEGATIONS: Rocket Pharmaceuticals operates as a late-stage biotechnology company that focuses on developing gene therapies for rare and devastating diseases. The Rocket Pharmaceuticals class
More news about: Robbins Geller Rudman & Dowd LLP
Jul 23, 2025, 11:36 ET European Commission Approved DARZALEX Faspro® for Adult Patients with Smouldering Multiple Myeloma
at least one major region and across more than 100 global markets, Halozyme has licensed its ENHANZE® technology to leading pharmaceutical and biotechnology companies including Roche, Takeda, Pfizer, Janssen, AbbVie, Eli Lilly, Bristol-Myers Squibb, argenx, ViiV Healthcare, Chugai Pharmaceutical and
More news about: Halozyme Therapeutics, Inc.
Jul 23, 2025, 11:33 ET SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Fortrea Holdings
from buy to hold. Among other things, the Jefferies Report cited perceived weaknesses in the Company's business model as a CRO amid pressure on biotechnology funding and suggested that the cost savings Fortrea expects to achieve by exiting the TSAs are "not as material as [o]ne [m]ight think," stating
More news about: Faruqi & Faruqi, LLP
Jul 23, 2025, 11:23 ET TOP SCIENCE TEACHERS ANNOUNCED FOR 12TH ANNUAL REGENERON STEM TEACHING FELLOWSHIP
students for college and careers in the STEM workforce. The STEM Teaching Fellowship is sponsored by Regeneron Pharmaceuticals, a leading biotechnology company based in Tarrytown, New York, that invents, develops and commercializes life-transforming medicines for
More news about: STEM Leadership Center
Jul 23, 2025, 10:01 ET Nuclear Medicine Software Market worth $1,491.55 million by 2030 with 9.0% CAGR | MarketsandMarkets™
software market has been segmented by end users into healthcare providers, pharmaceutical & biotechnology companies, medtech companies, and other end users. Among these, the pharmaceutical & biotechnology companies segment accounted for the largest market share due to the expansion of theranostics
More news about: MarketsandMarkets
Jul 23, 2025, 10:01 ET Global Conveyor Belt Market Experiences Rising Demand from Aviation and Manufacturing Sector Globally
syndicated and consulting research services. We specialize in semiconductor and electronics, aerospace and defense, automotive and transportation, biotechnology, healthcare IT, manufacturing and construction, medical devices, technology, media and telecommunications, and chemicals and materials. Contact
More news about: The Insight Partners
Jul 23, 2025, 09:39 ET Key Opinion Leader Event Highlights Pelareorep's Compelling Pancreatic and Gastrointestinal Data And Future Potential
of transforming outcomes in these difficult-to-treat cancers." About Oncolytics Biotech Inc. Oncolytics is a clinical-stage biotechnology company developing pelareorep, an intravenously delivered immunotherapeutic agent. Pelareorep has demonstrated promising results in two randomized
More news about: Oncolytics Biotech® Inc.
Jul 23, 2025, 09:24 ET Kelun-Biotech's Partner Windward Bio Announces Initiation of a Global Phase 2 Asthma Trial of SKB378/WIN378
About Windward Bio Windward Bio is a clinical-stage biotechnology company with deep discovery, development and commercialization expertise committed to transforming the treatment of people living with advanced
More news about: Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
Jul 23, 2025, 09:00 ET Debut Launches Plant Cell Biotechnology Creating Fragrance Ingredients Without Cultivation; Rare Orris is Inaugural Ingredient
Debut, the biotech beauty leader, announced that it has launched a plant cell biotechnology platform that enables the creation of fragrance ingredients, from simple to complex molecules, without the need for cultivation. The technology
More news about: Debut Biotechnology
Jul 23, 2025, 09:00 ET K18 LAUNCHES HEATBOUNCE™ -- THE FUTURE OF HEAT PROTECTION
mission is to liberate the freedom of self expression through healthy hair. Its patented K18PEPTIDE™, is a breakthrough ingredient developed from biotechnology that is revolutionizing the industry. Unlike traditional treatments, the K18PEPTIDE™ works at the molecular level, mimicking the natural structure
More news about: K18 Biomimetic Hairscience
Jul 23, 2025, 08:36 ET HBM9378/WIN378, a Long-Acting, Fully Human Anti-TSLP Antibody, Enters Global Phase 2 POLARIS Trial for Asthma
About Windward Bio AGWindward Bio is a clinical-stage biotechnology company with deep discovery, development and commercialization expertise committed to transforming the treatment of people living with advanced
More news about: Harbour BioMed
Jul 23, 2025, 06:00 ET Theravance Biopharma to Participate in an Upcoming Investor Conference
July 23, 2025 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ: TBPH) will participate in a fireside chat at the BTIG Virtual Biotechnology Conference on Wednesday, July 30 at 12:00 pm ET (9:00 am PT/
More news about: Theravance Biopharma, Inc.
Jul 23, 2025, 05:00 ET Trailhead Biosystems® Expands Human Cell-Based Product Line with iPSC-Derived A9 Dopaminergic Neurons
Ohio, July 23, 2025 /PRNewswire/ -- Trailhead Biosystems, Inc. (TrailBio.com), a biotechnology company pioneering the creation of induced pluripotent stem cell (iPSC)-derived human cells at scale for drug discovery and cell therapy, introduces TrailBio® A9
More news about: Trailhead Biosystems Inc
Jul 22, 2025, 17:31 ET ROR Inhibitors Market Expected to Witness Significant Growth Through 2034 Due to the Rising Oncology Research and Pipeline Advancements | DelveInsight
HNSCC companies, including Bristol Myers Squibb, Merck, Merus, Exelixis, ISA Pharmaceuticals, Regeneron Pharmaceuticals, PDS Biotechnology, BioNTech, Cue Biopharma, Immutep, Iovance Biotherapeutics, Inovio Pharmaceuticals, MedImmune, Nykode Therapeutics, RAPT Therapeutics, among
More news about: DelveInsight Business Research, LLP
Jul 22, 2025, 15:32 ET Oncolytics Biotech® Regains Compliance with Nasdaq Trading Rules
July 21, 2025, and the matter is now closed. About Oncolytics Biotech Inc. Oncolytics is a clinical-stage biotechnology company developing pelareorep, an intravenously delivered immunotherapeutic agent. Pelareorep has demonstrated promising results in two randomized
More news about: Oncolytics Biotech® Inc.
Jul 22, 2025, 10:21 ET Klotho Neurosciences, Inc. Partners with AAVnerGene Inc. to Make Klotho's Gene Therapy Assets
tissues and organs affected by these neurologic and neuromuscular diseases." About AAVnerGene, Inc. AAVnerGene is a creativity-powered biotechnology company pioneering next-generation AAV vector technologies. The company's proprietary platforms include AAVone, a high-yield, single-plasmid
More news about: Klotho Neurosciences, Inc.